



POCKET NO.: MOR-0241/HD0002US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Luigi Grasso, et al.

Application No.: 10/624,631

Filing Date: July 21, 2003

**For: METHODS FOR GENERATING ENHANCED ANTIBODY-PRODUCING
CELL LINES WITH IMPROVED GROWTH CHARACTERISTICS**

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: *October 3, 2003*

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date



DOCKET NO.: MOR-0241/HD0002US - 2 -

PATENT

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.


☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;
or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.



☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:

☒ In view of the voluminous nature of references 1,17, 24 and 41 and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:

☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. _____, filed _____.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.



DOCKET NO.: MOR-0241/HD0002US - 4 -

PATENT

The relevance of those listed references which are not in the English language is as follows:

☒ There are no listed references which are not in the English language.

Date: October 3, 2003

Felicity E. Groth
Felicity E. Groth
Registration No. 47,042


WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2003 WW




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0241/ HD0002US	Application No. 10/624,631
		Applicant Luigi Grasso, et al.	
		Filing Date July 21, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
*	1	Ausubel, et al., Current Protocols in Molecular Biology, <i>John Wiley & Sons, New York, 1998</i>	
	2	Baker, S.M., et al., "Male defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis," <i>Cell</i> , July 28, 1995 , 82, 309-319	
	3	Barr, P.J., et al., "Active site modified protease .alpha.-1-antitrypsin inhibitors, <i>Patent: US 4,732,973 A</i> , March 22, 1988 , <i>Chiron corp., Emeryville, CA</i> , GenBank Accession No. I00556, 2 pages	
	4	Bignami, M., "Unmasking a killer: DNA O ⁶ -methylguanine and the cytotoxicity of methylating agents," <i>Mutat. Res.</i> , 2000 , 462, 71-82	
	5	Bocker, T., et al., "hMSH5: a human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis," <i>Cancer Res.</i> , February 15, 1999 , 59, 816-822	
	6	Bronner, C.E., et al., "Mutation in the DNA mismatch repair gene homologue <i>hMLH1</i> is associated with hereditary non-polyposis colon cancer," <i>Nature</i> , 1994 , 368, 258-261	
	7	deWind, N., et al., "Inactivation of the mouse <i>Msh2</i> gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer," <i>Cell</i> , July 28, 1995 , 82, 321-330	
	8	Drummond, J.T., et al., "Isolation of an hMSH2-p160 heterodimer that restores mismatch repair to tumor cells," <i>Science</i> , June 30, 1995 , 268, 1909-1912	
	9	Drummond, J.T., et al., "Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line," <i>J. Biol. Chem.</i> , August 16, 1996 , 271(33), 19645-19648	
	10	Emery, S.C., et al., "Strategies for humanizing antibodies," In: Antibody Engineering C.A.K., Borrebaeck (Ed.), <i>Oxford University Press, NY</i> , 1995 , 159-183	
EXAMINER		DATE CONSIDERED	

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0241/ HD0002US	Application No. 10/624,631
		Applicant Luigi Grasso, et al.	
		Filing Date July 21, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Eshleman, J.R., et al., "Mismatch repair defects in human carcinogenesis," <i>Hum. Mol. Genet.</i> , 1996 , <i>5</i> , 1489-1494	
	12	Fan, Y., et al., "Endothelial-monocyte activating polypeptide (EMAP) I/S100C: A tumor-derived cytokine which activates host response mechanisms," <i>Unpublished</i> , GenBank Accession No. MMU41341, 2 pages	
	13	Fiedler, U., et al., "High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds," <i>Bio/Technology</i> , October 1995 , <i>13</i> , 1090-1093	
	14	Frigerio, L., et al., "Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants," <i>Plant Physiol.</i> , August 2000 , <i>123</i> , 1483-1494	
	15	Galio, L., et al., "ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL," <i>Nucl. Acids Res.</i> , 1999 , <i>27(11)</i> , 2325-2331	
	16	Glaser, V., "Can ReoPro repolish tarnished monoclonal therapeutics?," <i>Nat. Biotechnol.</i> , October 1996 , <i>14</i> , 1216-1217	
*	17	Kaufman, M.B., et al., Handbook of Molecular and Cellular Methods in Biology and Medicine, <i>CRC Press, Boca Raton</i> , 1995	
	18	Khazaeli, M.B., et al., "Human immune response to monoclonal antibodies," <i>J. Immunother.</i> , 1994 , <i>15</i> , 42-52	
	19	Koi, M., et al., "Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation," <i>Cancer Res.</i> , August 15, 1994 , <i>15</i> , 4308-4312	
	20	Lawson, W.B., et al., "Studies on the inhibition of human thrombin: effects of plasma and plasma constituents," <i>Folia Haematol</i> , 1982 , <i>109(1S)</i> , 52-60	
EXAMINER		DATE CONSIDERED	

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0241/ HD0002US	Application No. 10/624,631
	Applicant Luigi Grasso, et al.	
	Filing Date July 21, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	21	Lindor, N.M., et al., "Search for chromosome instability in lymphocytes with germ-line mutations in DNA mismatch repair genes," <i>Cancer Genet Cytogenet</i> , 1998 , 104, 48-51
	22	Lipkin, S.M., et al., MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability," <i>Nat. Genet.</i> , January 2000 , 24, 27-35
	23	Liu, T., et al., "Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer," <i>Genes Chromosomes Cancer</i> , 2000 , 27, 17-25
*	24	McPherson (Ed.), Directed Mutagenesis: A Practical Approach, <i>IRL Press, Oxford</i> , 1991
	25	Modrich, P., "Mismatch repair, genetic stability, and cancer," <i>Science</i> , December 23, 1994 , 266, 1959-1960
	26	Müller, A., et al., "Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC)," <i>Cancer Invest.</i> , 2002 , 20(1), 102-109
	27	Neuberger, M., et al., "Monoclonal antibodies: mice perform a human repertoire," <i>Nature</i> , March 6, 1997 , 386, 25-26
	28	Nicolaides, N.C., et al., "A naturally occurring <i>hPMS2</i> mutation can confer a dominant negative mutator phenotype," <i>Mol. Cell. Biol.</i> , March 1998 , 18(3), 1635-1641
	29	Nicolaides, N.C., et al., "Analysis of the 5' region of <i>PMS2</i> reveals heterogenous transcripts and a novel overlapping gene," <i>Genomics</i> , 1995 , 29, 329-334
	30	Nicolaides, N.C., et al., "Genomic organization of the human <i>PMS2</i> gene family," <i>Genomics</i> , 1995 , 30, 195-206
EXAMINER		DATE CONSIDERED

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0241/ HD0002US	Application No. 10/624,631
		Applicant Luigi Grasso, et al.	
		Filing Date July 21, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	31	Nicolaidis, N.C., et al., "The Jun family members, c-JUN and JUND, transactivate the human <i>c-myb</i> promoter via an Ap1 like element," <i>J. Biol. Chem.</i> , September 25, 1992, 267(27), 19665-19672	
	32	Nicolaidis, N.C., et al., "Interleukin 9: A candidate gene for asthma," <i>Proc. Natl. Acad. Sci. USA</i> , November 1997, 94, 13175-13180	
	33	Palombo, F., et al., "Mismatch repair and cancer," <i>Nature</i> , February 1994, 36, 417	
	34	Parsons, R., et al., "Hypermutability and mismatch repair deficiency in RER+ tumor cells," <i>Cell</i> , December 17, 1993, 75, 1227-1236	
	35	Papadopoulos, N., et al., "Mutation of a mutL homolog is associated with hereditary colon cancer," <i>Science</i> , 1993, 263, 1625-1629	
	36	Perucho, M., "Cancer of the microsatellite mutator phenotype," <i>Biol. Chem.</i> , November 1996, 377, 675-684	
	37	Prolla, T.A., et al., "MLH1, PMS1, and MSH2 interaction during the initiation of DNA mismatch repair in yeast," <i>Science</i> , August 19, 1994, 264, 1091-1093	
	38	Qian, Y., et al., "Molecular events after antisense inhibition of hMSH2 in a HeLa cell line," <i>Mutat Res.</i> , 1998, 418, 61-71	
	39	Reff, M.E., "High-level production of recombinant immunoglobulins in mammalian cells," <i>Curr. Opin. Biotechnol.</i> , 1993, 4, 573-576	
	40	Saez-Llorens, X.E., et al., "Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia," <i>Pediat. Infect. Dis. J.</i> , 1998, 17, 787-791	
EXAMINER		DATE CONSIDERED	




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0241/ HD0002US	Application No. 10/624,631
	Applicant Luigi Grasso, et al.	
	Filing Date July 21, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*	41	Sambrook, et al., <i>Molecular Cloning: A Laboratory Manual</i> , 2 nd Ed. <i>Cold Spring Harbor Laboratory Press, Plainview, NY, 1989</i>
	42	Shield, C.F., et al., "A cost-effective analysis of OKT3 induction therapy in cadaveric kidney transplantation," <i>Am. J. Kidney Dis.</i> , June 1996, 27(6), 855-864
	43	Shields, R.L., et al., "Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release," <i>Int. Arch. Allergy Immunol.</i> , 1995, 107, 412-413
	44	Strand, M., et al., "Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair," <i>Nature</i> , September 16, 1993, 365, 274-276
	45	Su, S.-S., et al., "Mispair specificity of methyl directed DNA mismatch corrections in vitro," <i>J. Biol. Chem.</i> , May 15, 1988, 263(14), 6829-6835
	46	Weiner, L.M., "Monoclonal antibody therapy of cancer," <i>Semin. In Oncol.</i> , October 1999, 26(5), Suppl. 14, 43-51
EXAMINER		
DATE CONSIDERED		

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0241/ HD0002US	Application No. 10/624,631
	Applicant Luigi Grasso, et al.	
	Filing Date July 21, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	47	4,732,973	03/22/88	Barr, et al.	530	350
	48	5,530,101	06/25/96	Queen, et al.	530	387.3
	49	6,146,894	11/14/00	Nicolaides, et al.	435	440

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	50	WO 02/054856	07/18/02	PCT		

EXAMINER

DATE CONSIDERED